Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 8935 results

  1. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development Reference number: GID-TA10990 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Oveporexton for treating type 1 narcolepsy [ID6622]

    Awaiting development Reference number: GID-TA11820 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  4. Avexitide for treating hypoglycaemia after bariatric surgery [ID6725]

    Awaiting development Reference number: GID-TA11824 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

    In development Reference number: GID-TA11508 Expected publication date:  29 July 2026

    Technology appraisal guidance
    In development

  6. Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726]

    Awaiting development Reference number: GID-TA11829 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]

    Awaiting development Reference number: GID-TA11954 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. DB-OTO for Hearing loss [ID6728]

    Awaiting development Reference number: GID-TA11911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Setrusumab for treating osteogenesis imperfecta [ID6730]

    Awaiting development Reference number: GID-TA11921 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. CM-AT for behaviours associated with autism in children and young people [ID6731]

    Awaiting development Reference number: GID-TA11955 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value Assessment

    In development Reference number: GID-HTE10067 Expected publication date:  20 May 2026

    Health technology evaluations
    In development

  12. DCVax-L for treating glioblastoma [ID836]

    In development Reference number: GID-TA10143 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development Reference number: GID-TA11298 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]

    In development Reference number: GID-TA11638 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]

    Awaiting development Reference number: GID-TA11855 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development